Cochrane · systematic review · CD010503
Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome
Naheed, B, Kuiper, JH, Uthman, OA, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 9 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oestrogen in combination with progestogen (sequential or continuous) compared to placebo for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptom scores over 2 to 4 menstrual cycles1 Oestrogen in combination with progestogen (sequential or continuous) vs placebo | no estimate extracted | 3 studies · 158 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Withdrawal due to adverse events over 2 to 4 menstrual cycles1 Oestrogen in combination with progestogen (sequential or continuous) vs placebo | RR 0.64 [0.26, 1.58] | 3 studies · 196 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Specific adverse events over 2 to 4 menstrual cycles1 Oestrogen in combination with progestogen (sequential or continuous) vs placebo | no estimate extracted | 206 participants | Very low |
Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global symptoms of PMS over 3 menstrual cycles1 Oestrogen vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: withdrawal due to adverse events over 3 menstrual cycles1 Oestrogen vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Specific adverse events over 3 menstrual cycles1 Oestrogen vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptoms score: Premenstrual Daily Questionnaire (PDQ) Scale from 0 to 30, with a higher score indicating a worse outcome over 8 months Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen | no estimate extracted | 1 study · 98 participants | Very low Downgraded: risk of bias |
Adverse events ‐ withdrawal rates over 8 months' Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen | RR 0.7 [0.34, 1.46] | 1 study · 107 participants | Very low Downgraded: risk of bias |
Adverse events ‐ specific side effects attributed to oestrogen over 8 months' Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen | RR 0.51 [0.26, 0.99] | 1 study · 107 participants | Very low Downgraded: risk of bias |